<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00445861</url>
  </required_header>
  <id_info>
    <org_study_id>SAKK 75/06</org_study_id>
    <secondary_id>EU-20702</secondary_id>
    <nct_id>NCT00445861</nct_id>
  </id_info>
  <brief_title>Cetuximab, Docetaxel, Cisplatin, and Radiation Therapy in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed by Surgery</brief_title>
  <official_title>Cetuximab in Combination With Radiation Therapy and Chemotherapy Prior to Surgery in Patients With Resectable, Locally Advanced Esophageal Carcinoma. A Multicenter Phase IB-II Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Swiss Group for Clinical Cancer Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Swiss Group for Clinical Cancer Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different&#xD;
      ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and&#xD;
      help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy, such as&#xD;
      docetaxel and cisplatin, work in different ways to stop the growth of tumor cells, either by&#xD;
      killing the cells or by stopping them from dividing. Radiation therapy uses high-energy&#xD;
      x-rays to kill tumor cells. Giving cetuximab, docetaxel, and cisplatin together with&#xD;
      radiation therapy before surgery may make the tumor smaller and reduce the amount of normal&#xD;
      tissue that needs to be removed.&#xD;
&#xD;
      PURPOSE: This phase I/II trial is studying the side effects of cetuximab, docetaxel,&#xD;
      cisplatin, and radiation therapy and to see how well they work in treating patients with&#xD;
      locally advanced esophageal cancer that can be removed by surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the safety of neoadjuvant radiotherapy in combination with cetuximab,&#xD;
           docetaxel, and cisplatin in patients with resectable locally advanced esophageal cancer.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the feasibility and efficacy of this regimen in these patients.&#xD;
&#xD;
        -  Determine the duration of response and patterns of failure in patients treated with this&#xD;
           regimen.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
        -  Chemoimmunotherapy: Patients receive cetuximab IV over 1-2 hours once weekly in weeks&#xD;
           1-3 and docetaxel IV over 1 hour and cisplatin IV over 1 hour once in week 1. Treatment&#xD;
           repeats every 3 weeks for 2 courses.&#xD;
&#xD;
        -  Chemoimmunotherapy and radiotherapy: Patients are sequentially assigned to 1 of 2&#xD;
           treatment levels.&#xD;
&#xD;
             -  Treatment level 1: Patients receive cetuximab IV over 1 hour once weekly, cisplatin&#xD;
                IV over 1 hour once weekly, and undergo radiotherapy once daily, 5 days a week, in&#xD;
                weeks 7-11.&#xD;
&#xD;
             -  Treatment level 2: Patients receive cetuximab, cisplatin, and radiotherapy as in&#xD;
                treatment level 1. Patients also receive docetaxel IV over 1-2 hours once weekly in&#xD;
                weeks 7-11.&#xD;
&#xD;
      Cohorts of 7-20 patients are treated at treatment level 1 or 2 sequentially, as long as no&#xD;
      more than 2 of 7 patients experience dose-limiting toxicity (DLT), until the safe treatment&#xD;
      level for future study is determined. The safe treatment level is defined as the level at&#xD;
      which no more than 2 of 7 and no more than 6 of 20 patients experience DLT. At least 20&#xD;
      patients are treated at the safe treatment level.&#xD;
&#xD;
        -  Surgery: Between 4-8 weeks after completion of neoadjuvant chemoimmunotherapy and&#xD;
           radiotherapy, patients undergo surgery.&#xD;
&#xD;
      After completion of study treatment, patients are followed every 3 months for 1 year, every 6&#xD;
      months for 3 years, and then annually thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 27 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the safety of neoadjuvant radiotherapy in combination with cetuximab, docetaxel, and cisplatin</measure>
    <time_frame>Until treatment ends</time_frame>
    <description>Determine the safety of neoadjuvant radiotherapy in combination with cetuximab, docetaxel, and cisplatin</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine the feasibility and efficacy of the study's regimen</measure>
    <time_frame>Until trial ends</time_frame>
    <description>Determine the feasibility and efficacy of this regimen in these patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the duration of response and patterns of failure</measure>
    <time_frame>Until trial ends</time_frame>
    <description>Determine the duration of response and patterns of failure in patients treated with this regimen</description>
  </secondary_outcome>
  <enrollment type="Actual">27</enrollment>
  <condition>Esophageal Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>cetuximab + docetaxel + cisplatin</intervention_name>
    <description>Chemoimmunotherapy: Patients receive cetuximab IV over 1-2 hours once weekly in weeks 1-3 and docetaxel IV over 1 hour and cisplatin IV over 1 hour once in week 1. Treatment repeats every 3 weeks for 2 courses.</description>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Treatment level 1</intervention_name>
    <description>Treatment level 1: Patients receive cetuximab IV over 1 hour once weekly, cisplatin IV over 1 hour once weekly, and undergo radiotherapy once daily, 5 days a week, in weeks 7-11.</description>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Treatment level 2</intervention_name>
    <description>Patients receive cetuximab, cisplatin, and radiotherapy as in treatment level 1. Patients also receive docetaxel IV over 1-2 hours once weekly in weeks 7-11.</description>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
    <description>Between 4-8 weeks after completion of neoadjuvant chemoimmunotherapy and radiotherapy, patients undergo surgery.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed squamous cell carcinoma or adenocarcinoma of the thoracic&#xD;
             esophagus&#xD;
&#xD;
               -  Carcinoma of the gastroesophageal junction (i.e., Siewert staging system type I&#xD;
                  disease) allowed&#xD;
&#xD;
          -  Locally advanced disease&#xD;
&#xD;
               -  Obstructive tumors are considered locally advanced disease&#xD;
&#xD;
               -  Meets 1 of the following staging criteria:&#xD;
&#xD;
                    -  T3, N0 disease&#xD;
&#xD;
                    -  T1-3, N1 disease&#xD;
&#xD;
                    -  T4, N0-1 disease&#xD;
&#xD;
          -  Resectable disease&#xD;
&#xD;
               -  No T4 (unequivocal organ involvement) disease that cannot be resected with&#xD;
                  curative intent&#xD;
&#xD;
          -  No airway infiltration in case of tumors of the upper third of the thoracic esophagus&#xD;
&#xD;
          -  No cervical esophageal carcinoma&#xD;
&#xD;
          -  No distant metastasis, including stage M1a (celiac node involvement) by fine-needle&#xD;
             aspiration or biopsy&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  WHO performance status 0-1&#xD;
&#xD;
          -  Creatinine clearance &gt; 60 mL/min&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 2.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST ≤ 1.5 times ULN&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm³&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm³&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 12 months after&#xD;
             completion of study treatment&#xD;
&#xD;
          -  No other malignancy within the past 5 years except nonmelanomatous skin cancer or&#xD;
             adequately treated in situ cervical cancer&#xD;
&#xD;
          -  No severe or uncontrolled cardiovascular disease including, but not limited to, any of&#xD;
             the following:&#xD;
&#xD;
               -  New York Heart Association class III or IV congestive heart failure&#xD;
&#xD;
               -  Unstable angina pectoris&#xD;
&#xD;
               -  Myocardial infarction within the past 3 months&#xD;
&#xD;
               -  Significant arrhythmias&#xD;
&#xD;
          -  No psychiatric disorder that would preclude study compliance&#xD;
&#xD;
          -  No active uncontrolled infection&#xD;
&#xD;
          -  No serious underlying medical condition that, in the opinion of the investigator,&#xD;
             would interfere with study participation (e.g., uncontrolled diabetes mellitus or&#xD;
             active autoimmune disease)&#xD;
&#xD;
          -  No peripheral neuropathy &gt; grade 1&#xD;
&#xD;
          -  No contraindications to corticosteroids&#xD;
&#xD;
          -  No known hypersensitivity to any component of the study drugs&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No prior chemotherapy&#xD;
&#xD;
          -  No prior radiotherapy to the chest&#xD;
&#xD;
          -  No participation in another clinical trial within the past 30 days&#xD;
&#xD;
          -  No other concurrent experimental drugs or anticancer therapy&#xD;
&#xD;
          -  No concurrent drugs contraindicated for use with the study drugs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Ruhstaller, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Cantonal Hospital of St. Gallen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kantonsspital - St. Gallen</name>
      <address>
        <city>St. Gallen</city>
        <zip>CH-9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik Stephanshorn</name>
      <address>
        <city>St. Gallen</city>
        <zip>Ch-9016</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <results_reference>
    <citation>Ruhstaller T, Pless M, Dietrich D, Kranzbuehler H, von Moos R, Moosmann P, Montemurro M, Schneider PM, Rauch D, Gautschi O, Mingrone W, Widmer L, Inauen R, Brauchli P, Hess V. Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: a prospective, multicenter phase IB/II Trial (SAKK 75/06). J Clin Oncol. 2011 Feb 20;29(6):626-31. doi: 10.1200/JCO.2010.31.9715. Epub 2011 Jan 4.</citation>
    <PMID>21205757</PMID>
  </results_reference>
  <verification_date>June 2012</verification_date>
  <study_first_submitted>March 7, 2007</study_first_submitted>
  <study_first_submitted_qc>March 7, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2007</study_first_posted>
  <last_update_submitted>June 8, 2012</last_update_submitted>
  <last_update_submitted_qc>June 8, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 11, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adenocarcinoma of the esophagus</keyword>
  <keyword>squamous cell carcinoma of the esophagus</keyword>
  <keyword>stage II esophageal cancer</keyword>
  <keyword>stage III esophageal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

